

10/602,413

- 2 -

PCA391-D1-01-CFP

RECEIVED
CENTRAL FAX CENTER

SEP 27 2006

REMARKS

Applicants' paper "After Final – Amendment and Reply under 37 C.F.R. § 1.116" was transmitted to the USPTO on September 8, 2006. The undersigned received a telephone call from Examiner Olsen on September 26, 2006. In the telephone call, Examiner Olsen indicated that an obviousness-type double patenting rejection of claims 58 and 59 over the parent U.S. Patent No. 6,602,829 B2, would be necessary, but otherwise pending claims 2, 3, 58, and 59 appeared to be allowable. Examiner Olsen requested that Applicants submit a proper terminal disclaimer to obviate the need for sending out a new Office Action and to place the application in better condition for allowance. The terminal disclaimer should be sent by facsimile directly to his desktop facsimile number, 571-273-9051 and also directly to the USPTO facsimile number 571-273-8300.

Without signifying agreement with the proposed new rejection, Applicants hereby comply with Examiner Olsen's request in order to advance prosecution and place the application in better condition for allowance. Enclosed with this paper is a **TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT** on Form PTO/SB/26 (09-08). Also enclosed is authorization to charge Applicants' deposit account with the terminal disclaimer fee under 37 C.F.R. § 1.20(d). As requested, applicants' entire submission is being sent by facsimile both to 571-273-9051 and also to 571-273-8300.

The undersigned can be reached by telephone or facsimile at the numbers provided below.

Respectfully submitted,

Date: September 27, 2006Claude F. Purchase, Jr.

Claude F. Purchase, Jr.
Reg. No. 47,871
Pfizer Inc.
2800 Plymouth Road
Ann Arbor, MI 48106
Tel. (734) 622-1692
Fax (734) 622-1553